Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

SingleNucleotide Polymorphisms as Biomarkers of Mepolizumab and Benralizumab Treatment Response in Severe Eosinophilic Asthma.

International journal of molecular sciences - 26 Jul 2024

Rojo-Tolosa Susana, Sánchez-Martínez José Antonio, Caballero-Vázquez Alberto, Pineda-Lancheros Laura Elena, González-Gutiérrez María Victoria, Pérez-Ramírez Cristina, Jiménez-Morales Alberto, Morales-García Concepción

Abstract excerpt

The most promising treatment options for severe uncontrolled asthma (SUA) have emerged in recent years with the development of monoclonal antibodies for blocking selective targets responsible for the underlying inflammation, such as mepolizumab and benralizumab. However, there is variability in treatment response that is not fully controlled. The variability of the response to mepolizumab and benralizumab could...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Anti-Asthmatic Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antibodies, Monoclonal, Humanized

Share to Asthma

Share to Biomarkers

Share to Polymorphism, Single Nucleotide

Share to Treatment Outcome

Source

Open in PubMed Open full text

Identifiers

PMID: 39125709
DOI: 10.3390/ijms25158139
PMCID: PMC11311889

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

SingleNucleotide Polymorphisms as Biomarkers of Mepolizumab and Benralizumab Treatment Response in Severe Eosinophilic Asthma.PMID 39125709Read ↗

Single cell RNA-seq discovery of blood biomarkers predicting treatment outcome in severe asthma patientsSemantic proximity Read ↗

Influence of Genetics on the Response to Omalizumab in Patients with Severe Uncontrolled Asthma with an Allergic Phenotype.Semantic proximity Read ↗

Genetic Variants Associated with Biological Treatment Response in Inflammatory Bowel Disease: A Systematic Review.Semantic proximity Read ↗

Reslizumab in the treatment of severe eosinophilic asthma: an update.Semantic proximity Read ↗

Association of interleukin 1 receptor-like 1 gene polymorphisms with eosinophilic phenotype in Japanese adults with asthma.Semantic proximity Read ↗

SNPs inFAM13AandIL2RBgenes are associated with FeNO in adult subjects with asthma.Semantic proximity Read ↗

CD3E as a new predictive biomarker of response to omalizumab treatment in asthma patients: Evidence from bioinformatic analysis.Semantic proximity Read ↗

The Effect of Mepolizumab on Blood Eosinophil Subtype Distribution and Granule Protein Gene Expression in Severe Eosinophilic AsthmaSemantic proximity Read ↗

Precision care in the treatment of pediatric asthma.Semantic proximity Read ↗

Biologics in severe asthma: from precision phenotyping to clinical remission.Semantic proximity Read ↗

Benralizumab for the add-on maintenance treatment of patients with severe asthma aged 12 years and older with an eosinophilic phenotype.Semantic proximity Read ↗

Pharmacogenetic investigation of efficacy response to mepolizumab in eosinophilic granulomatosis with polyangiitisSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.